Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director · Pres and CEO | January 01, 2024 | January 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,813 |
Ending reported balance
After 2024-01-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-01 · Exercise / conversion · Acquired 27,000 · Balance 50,938 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Row 2 · 2024-01-01 · Tax withholding · Disposed 9,125 · Balance 41,813 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 81,000 |
Reported balance
After 2024-01-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-01 · Exercise / conversion · Disposed 27,000 · Balance 81,000 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3: On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3: On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Other · Disposed 15,000 · Balance 21,462 F1: Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Row 2 · 2022-03-11 · Other · Disposed 21,462 · Balance 0 F3: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.12 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-11 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Employee Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 15,200 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement).
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
F5: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2024 Filed Jan 3, 2024 16:44 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000416 · doc4.xml · derivative · entry 3 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 27,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:44 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 9,125 | $1.05 | $9,581.25 |
DisclosureSEC source: 0001209191-24-000416 · doc4.xml · nonDerivative · entry 2 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,813 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:44 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 27,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-000416 · doc4.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 15,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044445 · doc4.xml · derivative · entry 3 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,725 Underlying: Common Stock · 15,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 4,437 | $9.81 | $43,526.97 |
DisclosureSEC source: 0001209191-23-044445 · doc4.xml · nonDerivative · entry 2 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,938 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 15,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044445 · doc4.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 17, 2023 Filed Mar 17, 2023 17:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 6,300 | $7.86 | $49,532.49 |
DisclosureSEC source: 0001209191-23-019743 · doc4.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 17:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 6,500 | $7.74 | $50,277.50 |
DisclosureSEC source: 0001209191-23-017626 · doc4.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 108,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007013 · doc4.xml · derivative · entry 2 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 378,000 | $0.00 Strike: $16.97 | $0.00 |
DisclosureSEC source: 0001209191-23-007013 · doc4.xml · derivative · entry 1 Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,000 Underlying: Common Stock · 378,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 17:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 62,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043928 · doc4.xml · derivative · entry 2 Manion Douglas J. · CIK 0001875875 · Pres and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,300 Underlying: Common Stock · 62,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 17:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 217,800 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0001209191-22-043928 · doc4.xml · derivative · entry 1 Manion Douglas J. · CIK 0001875875 · Pres and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,800 Underlying: Common Stock · 217,800 shares Expires 2032-07-31 F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:12 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerEmployee Performance Restricted Stock Unit · Derivative | 15,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005892 · wf-form4_164703313587429.xml · derivative · entry 4 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,200 shares Expires not disclosed F5 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:12 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $48.12 | Not disclosed |
DisclosureSEC source: 0001628280-22-005892 · wf-form4_164703313587429.xml · derivative · entry 3 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:12 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 21,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005892 · wf-form4_164703313587429.xml · nonDerivative · entry 2 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement). F3 · price: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:12 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005892 · wf-form4_164703313587429.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,462 F1 · kind: Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:02 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 21,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000342 · wf-form4_164142012159914.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,462 F1 · shares: The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| August 15, 2021 Filed Aug 17, 2021 08:30 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Performance Restricted Stock Unit · Derivative | 15,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-017169 · wf-form4_162920343662236.xml · derivative · entry 3 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 15,200 shares Expires 2024-03-14 F3 · derivative.exercise_price: Each Employee Performance Restricted Stock Unit ("PRSU") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the performance period from August 15, 2021, through March 14, 2024 (the "Performance Period") and satisfaction of a continuing service requirement. The reporting person was granted a "target" number of PRSUs equal to 50% of the number reported in Column 5. This Form 4 reports the "maximum" number of PRSUs, which equals 200% of "target" PRSUs, in order to reflect the maximum number of common shares issuable to the reporting person pursuant to the PRSUs. F4 · shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. F4 · derivative.exercise_date: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. F4 · derivative.underlying_shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. F4 · balance_after: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. Read SEC document |
| August 15, 2021 Filed Aug 17, 2021 08:30 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $48.12 | $0.00 |
DisclosureSEC source: 0001628280-21-017169 · wf-form4_162920343662236.xml · derivative · entry 2 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-08-15 F2 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on August 15, 2022, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| August 15, 2021 Filed Aug 17, 2021 08:30 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-017169 · wf-form4_162920343662236.xml · nonDerivative · entry 1 Manion Douglas J. · CIK 0001875875 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on August 15, 2022, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of November, February, May, and August. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.